Earli develops programmable genetic constructs that activate exclusively in cancer cells, prompting them to self-identify and undergo apoptosis. This technology addresses the challenge of early cancer detection and targeted therapy by enabling precise identification of malignant cells without affecting healthy tissue.
Funding
$79.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer detection methods often fail to identify malignant cells at an early stage, when treatment is most effective. Existing diagnostic techniques may also lack the specificity needed to distinguish between cancerous and healthy tissue, leading to potential overtreatment and harmful side effects.
Solution
Earli is developing programmable genetic constructs designed to activate exclusively within cancer cells. These constructs prompt the malignant cells to express unique identifiers, essentially "revealing" themselves for targeted detection. Furthermore, the activated constructs can trigger apoptosis, causing the cancer cells to self-destruct while sparing healthy tissue. This approach aims to improve early cancer detection and enable more precise, targeted therapies.
Target Audience
Earli's technology targets oncologists, diagnostic companies, and researchers focused on early cancer detection and targeted therapies.
Features
- Programmable DNA nanoplasmids that selectively activate in cancer cells based on unique genetic signatures.
- Synthetic biomarkers expressed by cancer cells upon activation of the genetic construct, facilitating early detection.
- Induction of apoptosis (programmed cell death) in cancer cells, triggered by the activated genetic construct.
- Highly specific targeting mechanism to minimize off-target effects on healthy cells.